InSilico lands drug discovery deal after Hong Kong IPO 英硅智能IPO后热度不减 再签8.88亿美元大单
The developer of AI-enabled drugs could get up to $888 million from the new deal but, without any viable products yet, its revenues rely on partner payments 英硅智能尚未实现盈利，且收入高度依赖大客户，业绩受BD交易首付款的确认时间而大幅波动。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.